Interview: Luis Almeida, CEO, Luzitin, Portugal
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
Luzitin, S.A. is an early-stage pharmaceutical company focused on investigating and developing innovative compounds to be used in Photodynamic Therapy (PDT) or Photodiagnosis (PDx) of cancer or other diseases, thus contributing to the human wellness.
Luzitin emerged as a spin-off company from an R&D partnership between Bluepharma, S.A. and the University of Coimbra, Portugal. The Luzitin’s starting intellectual property is a series of new photosensitizing drugs licensed-in from the University of Coimbra. In March 2011, these new photosensitizers have been awarded the INVENTA Prize, which honoured the most relevant Portuguese invention of the 2001-2010 decade.
Luzitin’s shareholders are Bluepharma, S.A., a venture capital firm (Portugal Ventures, S.A.), and the inventors of the patented drugs. Luzitin’s headquarters are located at S Martinho do Bispo, Coimbra, Portugal. Luis Almeida, MD, PhD (Chief Executive Officer), Luis Arnaut, PhD (Chief Scientific Officer), and Sérgio Simões, PharmD, PhD (Chairman), compose the Management Team (MT). All have over 20 years of experience in their fields, and altogether they cover all disciplines involved in drug R&D from bench to bedside.
Luzitin’s long-term goal is to become a leader in PDT or PDx of cancer and other selected indications by providing innovative products and services, and partnering with other companies and public research institutions to bring new products to market.
Luzitin is committed to reach proof-of-concept clinical trials (phase II) and afterwards to negotiate licensing terms with a pharmaceutical company to further co-develop and co-market its compounds.
Contact:
Luzitin, SA
Edifício Bluepharma – Rua da Bayer – S. Martinho do Bispo
3045-016 Coimbra
PORTUGAL
Phone: +351 239 800 300
Fax: +351 239 800 333
www.luzitin.pt
Luis Almeida, CEO of Luzitin Portugal, talks about the Innovation of the Decade award Luzitin received for its patented technology, what exactly is so unique and innovative about this technology,…
João Vasconcelos was the Secretary of State for Industry in Portugal over a two year period, terminating in July 2017, over which time he laid the foundations for Startup Portugal…
Pedro Moura is the first Portuguese managing director of Merck in Portugal, taking on the role in September 2017 after a stint in HQ in Darmstadt, Germany. Moura discusses Merck’s…
Enrique Santos, president of the Spanish Chamber of Commerce in Portugal since 1998, observes the rapid change in the volume and nature of investments into Portugal in recent years. Santos…
Azevedos is one of the oldest pharmaceutical brands in Portugal. Lead by Thebar Miranda, president for 30 years it operates across Portuguese speaking companies and distributes worldwide. In this interview,…
Florian Ibe, managing director at Bayer Portugal, discusses market access hurdles, as well as Portugal’s expertise in scientific and clinical research and highly educated workforce. In three years of his…
Paulo Lilaia, president of the board of APOGEN and CEO of Generis, highlights the need for generics in the healthcare system and the government’s approach to their implementation. He also…
The Portuguese secretary of state for industry invites readers to discover the vibrant tech landscape in Portugal. Ana Teresa Lehmann unravels the reasons why Portugal is such an exciting investment…
Filipa Costa returned to Portugal in September 2016 to take on the leadership of the fastest growing multinational affiliate in the country – Janssen. In this interview, she reveals her…
Heitor Costa, Executive Director for APIFARMA, the Portuguese Pharmaceutical Industry Association, outlines the recent improvements in industry and governmental agreements, the importance of non-prescription medicines, and raising societal awareness on…
A new regulation is helping Portugal’s market access conditions for pharmaceuticals catch up with those of other developed European markets, with a jump in the number of approvals for 2017.…
Graca Didier, secretary general of AmCham Portugal, discuss the role of her chamber of commerce in promoting strong relations between America and Portugal. In addition, she comments on the cultural…
Joaquim Cunha, executive director of Health Cluster Portugal – a private, non-profit organisation dedicated to the consolidation of Portugal’s healthcare industry – discusses the up and coming changes to the…
See our Cookie Privacy Policy Here
